Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease ...Middle East

SAN DIEGO, May 12, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for valbenazine as a treatment for Huntington disease (HD). The treatment of chorea associated...

Hence then, the article about neurocrine biosciences receives orphan drug designation for valbenazine as a treatment for chorea associated with huntington disease was published today ( Friday 13/05/2022 - 02:50 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease )

Also on site :

• What it takes to retire comfortably in America: Nearly $1.5 million, Northwestern Mutual says
• Europe’s cyber agency blames hacking gangs for massive data breach and leak
• Ukraine rocked by new multi-million-dollar corruption scandal